Barclays PLC Lineage Cell Therapeutics, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Barclays PLC holds 211,300 shares of LCTX stock, worth $135,232. This represents 0.0% of its overall portfolio holdings.

Number of Shares

211,300

Previous 211,300 -0.0%

Holding current value

$135,232

Previous $192,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$0.8 - $1.12 $127,939 - $179,114	159,924 Added 311.28%	211,300 $192,000
Q2 2024 Aug 14, 2024	SELL	$0.89 - $1.47 $37,870 - $62,549	-42,551 Reduced 45.3%	51,376 $51,000
Q1 2024 May 15, 2024	SELL	$0.86 - $1.48 $76,853 - $132,260	-89,365 Reduced 48.76%	93,927 $139,000
Q4 2023 Feb 15, 2024	BUY	$0.91 - $1.35 $144,959 - $215,049	159,296 Added 663.84%	183,292 $200,000
Q3 2023 Nov 07, 2023	SELL	$1.16 - $1.53 $2,214 - $2,920	-1,909 Reduced 7.37%	23,996 $28,000
Q2 2023 Aug 03, 2023	BUY	$1.26 - $1.53 $15,214 - $18,474	12,075 Added 87.31%	25,905 $36,000
Q1 2023 May 04, 2023	SELL	$1.2 - $1.53 $17,134 - $21,846	-14,279 Reduced 50.8%	13,830 $21,000
Q4 2022 Feb 13, 2023	BUY	$1.02 - $1.5 $20,881 - $30,708	20,472 Added 268.06%	28,109 $33,000
Q3 2022 Nov 03, 2022	BUY	$1.13 - $1.77 $8,629 - $13,517	7,637 New	7,637 $9,000
Q2 2022 Aug 12, 2022	SELL	$1.12 - $1.61 $22,803 - $32,779	-20,360 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$1.21 - $2.48 $24,635 - $50,492	20,360 New	20,360 $31,000

Others Institutions Holding LCTX

# of Institutions

121

Shares Held

94.2M

Call Options Held

63.8K

Put Options Held

View Full List

About Lineage Cell Therapeutics, Inc.

Ticker LCTX
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 169,755,008
Market Cap $109M
Description
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...

More about LCTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account